A Phase 1 interventional study of ICP-248 and Azacitidine in Acute Myelogenous Leukemia and Myelodysplastic Syndromes (MDS), sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.
Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 36th largest by planned enrollment of the 433 interventional ones that give a count, is one of 68 that started in 2024, is one of 121 in phase 1, reaches primary completion later than 171 of the 288 other live ones, and was the 340th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+
Beijing InnoCare Pharma Tech Co., Ltd. · Sites in China
Ages 18+
iCell Gene Therapeutics · Sites in China
Ages 18–70
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18+
Guangdong Second Provincial General Hospital · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
473 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 187 · Phase 2 191 · Phase 3 77 · Phase 4 13
First in 2003; this study’s year is marked. 68 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 266 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 50 across the 433 interventional studies, 100 across the 39 observational. Of the 72 that completed or were terminated, 9 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
115 of 473 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing InnoCare Pharma Tech Co., Ltd., one of the names counted as InnoCare Pharma Limited. Under that name alone:
Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.
InnoCare Pharma Limited has 2 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
71 of the studies in Leukemia, Myeloid, Acute with a site in China that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06802718Phase 3Peking University People's HospitalInterferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia | 2026-12 |
| NCT07712848Phase 3The Second Affiliated Hospital of Kunming Medical UniversityDEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | 2026-12-01 |
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT06990321Phase 3Yehui TanEffectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia | 2026-12-31 |
| NCT06345365Phase 3Zhongnan HospitalMA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | 2026-12-31 |
Add all 71 to your calendar (.ics) → With an account.
Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligible subjects must meet all of the following criteria:
For AML (except for APL) cohort:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ICP-248 · Drug: Azacitidine
Eligible patients will receive ICP-248 orally as per the protocol,once daily for every 28 days as one treatment cycle
Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol,once daily on days 1-7 of each 28-day cycle.
Incidence, type, and severity of dose-limiting toxicity (DLT).
Time frame: 2.5 years
Recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD).
Time frame: 2.5 years
The incidence, nature, and severity of adverse events (AEs) as assessed per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0) criteria.
Time frame: 2.5 years
AML cohort:Composite complete remission rate by Investigator per ELN 2017 criteria.
Time frame: 2.5 years
AML cohort:Composite complete remission rate by completion of cycle 2 by Investigator per ELN 2017 criteria.
Time frame: 2.5 years
MDS cohort:mOR rate, including CR, mCR, and PR, assessed by Investigator at any time point during the study per revised IWG 2006 MDS Criteria.
Time frame: 2.5 years
AML cohort:Composite complete remission rate: The proportion of subjects with complete remission (CR) and CR with incomplete hematologic recovery (CRi) by Investigator per European Leukemia Net (ELN) 2017 criteria.
Time frame: 2.5 years
AML cohort:Composite complete remission rate by completion of cycle 2 by Investigator per ELN 2017 criteria.
Time frame: 2.5 years
The incidence, nature, and severity of adverse events (AEs) as assessed per NCI-CTCAE v5.0 criteria.
Time frame: 2.5 years
Maximum concentration (Cmax)of ICP-248.
Time frame: 2.5 years
Area under the curve (AUC) of ICP-248.
Time frame: 2.5 years
Time of maximum observed plasma(Tmax)of ICP-248.
Time frame: 2.5 years
Trough concentration(Ctrough) of ICP-248.
Time frame: 2.5 years
Apparent clearance (CL/F) of ICP-248.
Time frame: 2.5 years
AML cohort:Partial Response (PR) by investigator per ELN 2017 criteria.
Time frame: 2.5 years
AML cohort:Overall survival (OS) by investigator per ELN 2017 criteria.
Time frame: 2.5 years
AML cohort:Duration of Response (DOR) by investigator per ELN 2017 criteria.
Time frame: 2.5 years
AML cohort:Event-free Survival (EFS) by investigator per ELN 2017 criteria.
Time frame: 2.5 years
AML cohort:Relapse-free Survival (RFS) by investigator per ELN 2017 criteria.
Time frame: 2.5 years
AML cohort:Morphologic leukemia-free state (MLFS) by investigator per ELN 2017 criteria.
Time frame: 2.5 years
MDS cohort:Modified overall response (mOR) rate, including CR, marrow complete response (mCR), and PR, assessed by Investigator at any time point during the study per revised International Working Group (IWG) 2006 MDS Criteria
Time frame: 2.5 years
MDS cohort:Complete remission(CR) rate by Investigator per revised IWG 2006 MDS Criteria
Time frame: 2.5 years
MDS cohort:Event-free survival (EFS) by Investigator per revised IWG 2006 MDS Criteria
Time frame: 2.5 years
MDS cohort:Duration of modified overall response (DmOR) by Investigator per revised IWG 2006 MDS Criteria
Time frame: 2.5 years
MDS cohort:Overall survival(OS) by Investigator per revised IWG 2006 MDS Criteria
Time frame: 2.5 years
MDS cohort:Marrow complete response (mCR) rate by Investigator per revised IWG 2006 MDS Criteria
Time frame: 2.5 years
Started Dec 2024 (actual). Primary completion is estimated for Jun 2027, 30 months after the start.
Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 30 months is below that.
Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mesutoclax
Beijing InnoCare Pharma Tech Co., Ltd. →